NCT02453087View on ClinicalTrials.gov

A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 4, 2015

Primary Completion Date

July 12, 2019

Study Completion Date

July 12, 2019

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

DCDS0780A

Participants will receive escalating doses of DCDS0780A as intravenous infusion.

DRUG

Rituximab

Participants will receive rituximab at a dose of 375 mg/m\^2 of body surface area as intravenous infusion.

DRUG

Obinutuzumab

Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.

Trial Locations (7)

10016

New York University Cancer Cen, New York

20007

Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.

34232

Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota

80012

Medical Center of Aurora; Rocky Mountain Cancer Centers, Aurora

91010

City of Hope National Medical Center, Duarte

94305-5820

Stanford Cancer Center, Stanford

97401-8122

Willamette Valley Cancer Ctr - 520 Country Club, Eugene

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02453087 - A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter